Skip to main content

Table 6 Meta-analyses of studies of specific myeloid maligancy type for benzene.*

From: The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

Characteristics No. of estimates Meta-RR estimate (95%CI) I2 test (%) p-value Egger’s test
ML
 Overall 7 1.56 (1.10–2.20) 45.06 0.0114 0.0063**
  High exposure 4 1.28 (0.87–1.88) 40.98 0.2051 0.0984
  Low exposure 1 2.24 (0.65–7.71) NA 0.2012 NA
  Any exposure 2 2.15 (1.29–3.58) 0.00 0.0033 NA
 Study type
  Case-control studies 0     NA
  Cohort studies 7 1.56 (1.10–2.20) 45.06 0.0114 0.0063**
AML
 Overall 27 1.30 (1.09–1.55) 48.91 0.0037 0.0155**
  High exposure 8 1.65 (1.13–2.41) 46.97 0.0100 0.1176
  Low exposure 5 1.54 (0.89–2.66) 58.71 0.1248 0.2679
  Any exposure 14 1.14 (0.93–1.39) 36.29 0.2057 0.3933
 Study type
  Case-control studies 9 1.34 (1.03–1.75) 40.12 0.0281 0.5929
  Cohort studies 18 1.29 (1.02–1.63) 51.98 0.0364 0.0119**
CML
 Overall 18 1.25 (1.00–1.55) 0.00 0.0456 0.2347
  High exposure 3 2.79 (1.44–5.40) 0.00 0.0024 0.7110
  Low exposure 2 1.93 (0.64–5.82) 0.00 0.2447 NA
  Any exposure 13 1.11 (0.87–1.40) 0.00 0.4019 0.4132
 Study type
  Case-control studies 5 1.93 (1.05–3.56) 25.76 0.0353 0.6999
  Cohort studies 13 1.13 (0.89–1.45) 0.00 0.3215 0.3540
MDS
 Overall 9 1.87 (1.39–2.52) 40.73 < 0.0001 0.0560
  High exposure 6 1.80 (1.18–2.75) 51.97 0.0065 0.1173
  Low exposure 2 2.29 (1.51–3.48) 0.00 < 0.0001 NA
  Any exposure 1 1.64 (0.83–3.22) N/A 0.1510 NA
 Study type
  Case-control studies 5 1.85 (1.28–2.67) 33.43 0.0012 0.5538
  Cohort studies 4 1.94 (1.19–3.18) 43.78 0.0081 0.1088
  1. *MPN not included as only one published point estimate was identified.**statistically significant (p. < 0.05)
\